title: Medical options in the management of stages 1 and 2 (N0-N3, M0) testicular germ cell tumors.
abstract: Retroperitoneal lymph-node dissection or radiotherapy have long been known to provide equivalent survival for early stage I and stage II nonseminomatous germ-cell tumors. Review of the results from intensive radiological and biochemical surveillance with salvage chemotherapy for stage I tumors demonstrates that the long-term survival rate is equivalent to that achievable by conventional treatment (i.e., 98 per cent survival at 4 years). As relapses have continued to occur in the third and fourth years at the rate of 4 per cent annually, and 4 years is the limit of follow-up, further follow-up is required to be sure of the long-term picture. Prognostic factor analysis demonstrates that venous and lymphatic invasion, the absence of yolk sac differentiation, and the presence of undifferentiated cells are independently important in predicting the frequency of relapse. Using these factors, it was possible to define low-risk groups with relapse rates less than that seen after lymph-node dissection and high-risk groups with 58 per cent frequency of relapse who probably are suitable for adjuvant chemotherapy studies. Review of the results from the use of surveillance in stage I seminoma demonstrated no advantages over prophylactic radiotherapy. However, late toxicity is being demonstrated after radiotherapy and evidence is emerging that the less toxic cisplatinum analogue carboplatin may be as good as radiotherapy for metastatic disease. This offers for the first time a viable alternative to radiotherapy for consideration in the adjuvant setting in stage I seminoma.
authors.affiliation: London Hospital Medical College, England.
authors.forename: R T
authors.initials: RT
authors.lastname: Oliver
authors.forename: L S
authors.initials: LS
authors.lastname: Freedman
authors.forename: M C
authors.initials: MC
authors.lastname: Parkinson
authors.forename: M J
authors.initials: MJ
authors.lastname: Peckham
mesh_terms: D003131:Combined Modality Therapy; D004407:Dysgerminoma / Q000628:therapy; D006801:Humans; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000628:therapy*; D012307:Risk Factors; D013736:Testicular Neoplasms / Q000628:therapy*